Sigma Planning Corp Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Sigma Planning Corp purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 15,000 shares of the biotechnology company’s stock, valued at approximately $300,000.

A number of other hedge funds have also added to or reduced their stakes in ADMA. D. E. Shaw & Co. Inc. lifted its stake in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after purchasing an additional 1,442,799 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after buying an additional 92,281 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after buying an additional 447,743 shares in the last quarter. Renaissance Technologies LLC grew its position in ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after acquiring an additional 575,100 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in ADMA Biologics by 15.5% in the second quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company’s stock valued at $22,022,000 after acquiring an additional 263,677 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James upped their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

Insiders Place Their Bets

In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now directly owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. This represents a 5.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jerrold B. Grossman sold 136,861 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $17.27, for a total value of $2,363,589.47. Following the sale, the director now owns 467,305 shares of the company’s stock, valued at approximately $8,070,357.35. The trade was a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $19.04 on Friday. The business has a 50 day moving average of $18.54 and a 200-day moving average of $14.34. The company has a market capitalization of $4.44 billion, a P/E ratio of 68.00 and a beta of 0.64. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter last year, the firm earned $0.01 earnings per share. On average, equities research analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.